Roivant Sciences to Accelerate Brepocitinib Phase III Launch in 2026 Following Positive Trial Results
ByAinvest
Friday, Feb 6, 2026 3:50 pm ET1min read
ROIV--
Roivant Sciences has announced multiple pivotal trial readouts and accelerated the launch of brepocitinib Phase III in 2026. CEO Matthew Gline highlighted positive Phase II results for brepocitinib in cutaneous sarcoidosis and the company's financial results for Q3 2025. The NDA for brepocitinib is under review by the FDA.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet